391 related articles for article (PubMed ID: 25630411)
1. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.
Bergen PJ; Bulman ZP; Saju S; Bulitta JB; Landersdorfer C; Forrest A; Li J; Nation RL; Tsuji BT
Pharmacotherapy; 2015 Jan; 35(1):34-42. PubMed ID: 25630411
[TBL] [Abstract][Full Text] [Related]
2. Rational Combinations of Polymyxins with Other Antibiotics.
Bergen PJ; Smith NM; Bedard TB; Bulman ZP; Cha R; Tsuji BT
Adv Exp Med Biol; 2019; 1145():251-288. PubMed ID: 31364082
[TBL] [Abstract][Full Text] [Related]
3. To B or not to B, that is the question: is it time to replace colistin with polymyxin B?
Kassamali Z; Danziger L
Pharmacotherapy; 2015 Jan; 35(1):17-21. PubMed ID: 25346395
[TBL] [Abstract][Full Text] [Related]
4. Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Polymyxins: Implications for Therapeutic Use.
Nation RL; Forrest A
Adv Exp Med Biol; 2019; 1145():219-249. PubMed ID: 31364081
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?
Bergen PJ; Landersdorfer CB; Zhang J; Zhao M; Lee HJ; Nation RL; Li J
Diagn Microbiol Infect Dis; 2012 Nov; 74(3):213-23. PubMed ID: 22959816
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J
Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
[TBL] [Abstract][Full Text] [Related]
7. Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria.
Bergen PJ; Bulman ZP; Landersdorfer CB; Smith N; Lenhard JR; Bulitta JB; Nation RL; Li J; Tsuji BT
Infect Dis Ther; 2015 Dec; 4(4):391-415. PubMed ID: 26645096
[TBL] [Abstract][Full Text] [Related]
8. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.
Nation RL; Li J; Cars O; Couet W; Dudley MN; Kaye KS; Mouton JW; Paterson DL; Tam VH; Theuretzbacher U; Tsuji BT; Turnidge JD
Lancet Infect Dis; 2015 Feb; 15(2):225-34. PubMed ID: 25459221
[TBL] [Abstract][Full Text] [Related]
9. An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics.
Kassamali Z; Jain R; Danziger LH
Int J Infect Dis; 2015 Jan; 30():125-32. PubMed ID: 25461655
[TBL] [Abstract][Full Text] [Related]
10. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.
Zavascki AP; Goldani LZ; Li J; Nation RL
J Antimicrob Chemother; 2007 Dec; 60(6):1206-15. PubMed ID: 17878146
[TBL] [Abstract][Full Text] [Related]
11. Polymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: from pharmacokinetics to bedside.
Zavascki AP
Expert Rev Anti Infect Ther; 2014 May; 12(5):531-3. PubMed ID: 24666285
[TBL] [Abstract][Full Text] [Related]
12. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).
Tsuji BT; Pogue JM; Zavascki AP; Paul M; Daikos GL; Forrest A; Giacobbe DR; Viscoli C; Giamarellou H; Karaiskos I; Kaye D; Mouton JW; Tam VH; Thamlikitkul V; Wunderink RG; Li J; Nation RL; Kaye KS
Pharmacotherapy; 2019 Jan; 39(1):10-39. PubMed ID: 30710469
[TBL] [Abstract][Full Text] [Related]
13. Multidrug-resistant Gram-negative infections: the use of colistin.
Michalopoulos AS; Karatza DC
Expert Rev Anti Infect Ther; 2010 Sep; 8(9):1009-17. PubMed ID: 20818945
[TBL] [Abstract][Full Text] [Related]
14. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis.
Zusman O; Altunin S; Koppel F; Dishon Benattar Y; Gedik H; Paul M
J Antimicrob Chemother; 2017 Jan; 72(1):29-39. PubMed ID: 27624572
[TBL] [Abstract][Full Text] [Related]
15. Treatment of infections caused by Gram-negative pathogens: current status on the pharmacokinetics/pharmacodynamics of parenteral and inhaled polymyxins in patients.
Lin YW; Aye SM; Rao G; Zhou QT; Chan HK; Li J
Int J Antimicrob Agents; 2020 Dec; 56(6):106199. PubMed ID: 33075510
[TBL] [Abstract][Full Text] [Related]
16. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria.
Evans ME; Feola DJ; Rapp RP
Ann Pharmacother; 1999 Sep; 33(9):960-7. PubMed ID: 10492501
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.
Velkov T; Roberts KD; Nation RL; Thompson PE; Li J
Future Microbiol; 2013 Jun; 8(6):711-24. PubMed ID: 23701329
[TBL] [Abstract][Full Text] [Related]
18. Polymyxin B versus colistin: an update.
Cai Y; Lee W; Kwa AL
Expert Rev Anti Infect Ther; 2015; 13(12):1481-97. PubMed ID: 26488563
[TBL] [Abstract][Full Text] [Related]
19. Polymyxin B: similarities to and differences from colistin (polymyxin E).
Kwa A; Kasiakou SK; Tam VH; Falagas ME
Expert Rev Anti Infect Ther; 2007 Oct; 5(5):811-21. PubMed ID: 17914915
[TBL] [Abstract][Full Text] [Related]
20. Bioanalysis and Stability of Polymyxins.
Milne RW
Adv Exp Med Biol; 2019; 1145():73-87. PubMed ID: 31364072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]